11th PAGE Meeting

Paris - France
6 - 7 June, 2002

View abstracts

Home / 2002 – Paris – France / Abstracts

← Back to filters

Abstracts (22)

Iñaki F. Trocóniz*, Ilonka Zsolt**, María J. Garrido*, Marta Valle**, and Manel J. Barbanoj**

Dealing with Autoinhibition of Drug Clearance in Early Clinical Product Development

Oscar Della Pasqua(1) and Eliane Fuseau(2)

Optimising Design In Paediatric Regulatory Studies

Eric Snoeck

Model Evaluation

Jose Pinheiro

Transformations and Variance Functions in Nonlinear Mixed-Effects Models

Charles Warlow

Sub-group Nonsense. Problems In Interpreting And Considering Covariates In Evaluation

Christian Laveille, PharmD (1), Lewis Sheiner, MD (2), Vincent Duval, PharmD (1), Guillemette Resplandy, PhD (1), and Roeline Jochemsen, PhD (1)

Simulations using a mechanistic DDI model: individual risk assessment.

Lewis Sheiner, MD.

Dealing With Missing Data Through Random Effects Models

Brigitte Tranchand1, Silvy Laporte2

Design and practical problems in population PK studies in the elderly

Sylvie Retout, France Mentré

Optimisation Of Individual And Population Pharmacokinetic Designs Using S-Plus

Jan Freijer, Bart Ploeger, Joost DeJongh & Meindert Danhof

Extrapolation of pharmacokinetics and toxicity from pre-clinical data to humans

Freidig A, Onderwater R, Bogaards J, Bouzom F and Jochemsen R.

Development of a PBPK model for drug-drug interaction of orally delivered drugs using in-vitro data

Billy Amzal - Frédéric Bois

Bayesian Optimal Design for the Study of Butadiene Toxicokinetics

Marie Gårdmark

Regulatory aspects of population pharmacokinetic drug interaction studies

Nick Holford, Jianguo Li, Lisa Benincosa, Mattias Birath

Population Disease Progress Models for the Time Course of HAMD Score in Depressed Patients Receiving Placebo in Anti-Depressant Clinical Trials

Vladimir Piotrovsky

Drug Efficacy Analysis as an Exercise in Dynamic (Indirect-Response) Population PK-PD Modeling

Stephen Duffull and Bruce Green

Prospective assessment of a D-optimal design for a population pharmacokinetic study of enoxaparin

Bruce Green and Stephen Duffull

Population pharmacokinetics and pharmacodynamics of enoxaparin in obese patients

R. H. Leary(1), R. Jelliffe(2), A. Schumitzky(2), and M. Van Guilder(2)

A Unified Parametric/Nonparametric Approach to PK/PD Population Modeling

Elena Mishina and Mehul Mehta

Assessment of the Contribution of Components in a Combination Drug Product Using Population PK Modeling

Stefano Zamuner, Roberto Gomeni, Alan Bye

Estimate the time varying brain receptor occupancy in PET imaging

Mick Looby

Assessing the robustness of competing dose regimens to incomplete compliance

Celine Brochot, William Couet, Andrew Gelman, Frederic Yves Bois

Assessing the Additivity of the Effects of Drugs in Mixtures